Equities

Ainos Inc

Ainos Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.485
  • Today's Change0.005 / 1.08%
  • Shares traded232.44k
  • 1 Year change-84.84%
  • Beta1.4347
Data delayed at least 15 minutes, as of Nov 11 2024 20:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

  • Revenue in USD (TTM)65.12k
  • Net income in USD-15.41m
  • Incorporated1984
  • Employees46.00
  • Location
    Ainos Inc8880 Rio San Diego Drive, Ste. 800SAN DIEGO 92108United StatesUSA
  • Phone+1 (858) 869-2986
  • Websitehttps://www.ainos.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Organovo Holdings Inc73.00k-13.99m6.17m12.00--0.8664--84.53-1.39-1.390.00690.46350.006--0.74113,650.00-115.47-54.25-136.97-58.4250.68---19,160.27-1,890.163.38--0.00---70.54-48.7815.00---11.87--
Carmell Corp12.32k-15.97m6.21m9.00------503.97-1.53-1.440.0006-0.0656------1,368.89--------58.73---129,263.60--0.6901-----------75.70------
Clearmind Medicine Inc0.00-8.44m6.25m----1.76-----12.73-12.730.000.87280.00-------133.31-218.20-266.82-488.96-----------2.600.0172-------25.03------
BioNexus Gene Lab Corp9.18m-2.21m6.30m30.00--0.6491--0.6862-0.1108-0.11080.58070.54030.96477.195.77---23.17-3.83-27.98-5.0213.8814.55-24.02-3.044.87-118.920.00---10.60115.07-638.56--30.40--
Enzon Pharmaceuticals Inc26.00k314.00k6.31m0.0020.092.08--242.620.00420.00420.00040.62770.0006------3.39-0.86543.42-0.8851----6,111.54-159.43----0.00---100.00--106.71-55.86----
Brainstorm Cell Therapeutics Inc0.00-12.75m6.38m29.00---------3.36-3.360.00-0.66420.00----0.00-223.03-117.19---231.65--------------------29.18---45.34--
Mosaic Immunoengineering Inc0.00-1.21m6.52m3.00---------0.1674-0.16740.00-0.89040.00----0.00-634.64-----------------14.05--------57.65------
ABVC Biopharma Inc136.40k-11.37m6.54m16.00--0.7651--47.95-1.78-1.780.01720.68820.0114--0.42138,525.00-99.79-103.38-197.79-231.54-24.1176.25-8,762.13-2,019.89---2.500.1873---84.2885.3935.97------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m6.60m389.000.00120.00010.71520.11590.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Ainos Inc65.12k-15.41m6.64m46.00--0.1712--101.96-3.17-3.170.01262.800.00190.781413.861,415.65-44.29-36.36-49.13-58.33-316.6236.82-23,664.28-813.631.45-55.500.4016---96.539.461.69--66.44--
Adial Pharmaceuticals Inc0.00-12.19m6.66m4.00--1.04-----5.26-5.300.000.99610.00----0.00-279.27-182.35-320.96-235.45-----------14.250.00------35.14------
Alzamend Neuro Inc0.00-7.39m6.67m4.00---------10.69-10.690.00-1.410.00----0.00-344.10-177.86---257.81-----------363.62--------33.14------
Aptorum Group Ltd431.38k-2.82m6.73m3.00--0.2565--15.60-0.9126-0.91260.09544.800.020830.363.88143,793.30-20.92-40.45-19.62-42.362.45-4.04-1,006.30-1,233.681.18--0.1694---66.712.3871.18---78.15--
Cyclerion Therapeutics Inc0.00-10.47m6.86m1.00--0.7247-----4.261.270.003.490.00----0.00-103.82-72.70-150.23-86.96-------2,565.62----0.00---100.00--30.98------
Viracta Therapeutics Inc0.00-45.34m7.11m40.00---------1.16-1.160.000.06780.00----0.00-83.82-86.35-140.98-106.38-------11,853.94---59.780.8753-------3.78------
Data as of Nov 11 2024. Currency figures normalised to Ainos Inc's reporting currency: US Dollar USD

Institutional shareholders

1.08%Per cent of shares held by top holders
HolderShares% Held
Two Sigma Securities LLCas of 30 Jun 202421.13k0.26%
Geode Capital Management LLCas of 30 Jun 202420.36k0.25%
BlackRock Fund Advisorsas of 30 Jun 202415.33k0.19%
Virtu Americas LLCas of 30 Jun 202413.15k0.16%
Tower Research Capital LLCas of 30 Jun 20248.77k0.11%
UBS Securities LLCas of 30 Jun 20248.40k0.10%
BofA Securities, Inc.as of 30 Jun 202455.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202428.000.00%
CWM LLCas of 30 Sep 20247.000.00%
Arbor Point Advisors LLCas of 30 Jun 20243.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.